Post-Transplant Lymphoproliferative Disorder

Post-transplant lymphoproliferative disorder (PTLD) is a heterogeneous group of lymphoid (and occasionally plasmacytic) proliferations that arise after transplantation as a consequence of immunosuppression. Most cases are driven by Epstein-Barr virus, and the disorder spans a continuum from early polyclonal lesions to aggressive monomorphic lymphomas, making it the most important transplant-associated lymphoid malignancy.

Definition

Post-transplant lymphoproliferative disorder is a lymphoid or plasmacytic proliferation that develops in a recipient of a solid-organ or hematopoietic stem-cell transplant as a result of immunosuppression; it ranges from early, often polyclonal hyperplastic lesions to polymorphic and monomorphic lymphomas and classic Hodgkin-type disease, the majority of which are associated with Epstein-Barr virus.

Scope

This topic introduces the definition and disease spectrum of PTLD, the central role of Epstein-Barr virus and reduced T-cell surveillance, the principal risk factors, and the recognized pathologic categories. It is reference-educational and does not provide staging, treatment, or immunosuppression-management instructions.

Core questions

• How does Epstein-Barr virus drive most cases of PTLD?
• Why does the spectrum of PTLD range from polyclonal lesions to monomorphic lymphoma?
• What factors raise the risk of PTLD, and why is EBV-seronegative status important?
• How is PTLD categorized pathologically?

Key concepts

• Epstein-Barr virus (EBV) driven B-cell proliferation
• Loss of EBV-specific T-cell surveillance
• Disease spectrum: early lesions, polymorphic, monomorphic, classic Hodgkin-type
• EBV-positive versus EBV-negative PTLD
• Risk factors: EBV D+/R- mismatch, degree of immunosuppression, recipient age
• Reduction of immunosuppression as a conceptual first response

Mechanisms

Most PTLD arises when immunosuppression reduces the EBV-specific cytotoxic T-cell responses that normally restrain EBV-infected B cells; uncontrolled proliferation of these cells can progress along a spectrum from polyclonal hyperplasia toward clonal, monomorphic lymphoma. A minority of cases are EBV-negative and tend to occur later, suggesting partly distinct pathways. Risk is greatest when an EBV-seronegative recipient receives an organ from a seropositive donor (primary EBV infection under immunosuppression), and it rises with the intensity of immunosuppression. Because the disorder is partly a failure of immune surveillance, reduction of immunosuppression is conceptually a foundational element of management, as described in reviews of the disorder.

Clinical relevance

PTLD is a leading transplant-associated malignancy and a recognized cause of morbidity and mortality, so awareness of its risk factors and presentations informs long-term surveillance of recipients. This entry explains the biology, classification, and risk concepts of PTLD for orientation only; it does not provide diagnostic criteria for individual patients, treatment regimens, or immunosuppression-adjustment guidance.

Epidemiology

PTLD is among the most characteristic cancers of the transplant population, and registry data such as Engels and colleagues' linkage show markedly elevated rates of non-Hodgkin lymphoma after solid-organ transplantation. Incidence varies by transplanted organ, the intensity and type of immunosuppression, recipient age, and especially EBV serostatus, with EBV-seronegative recipients of seropositive organs at the highest risk; many EBV-positive cases occur relatively early after transplant, whereas EBV-negative disease tends to present later.

History

Lymphoid proliferations after transplantation were recognized as immunosuppression-related early in the transplant era, and the association with Epstein-Barr virus clarified much of the biology. The disorder was subsequently organized into a graded pathologic spectrum within the World Health Organization lymphoma classifications, and modern reviews synthesize its mechanisms, categories, and risk factors, establishing PTLD as a distinct and clinically important entity.

Key figures

• Daan Dierickx
• Thomas M. Habermann
• Eric A. Engels

Seminal works

• dierickx-2018

Frequently asked questions

What causes most cases of post-transplant lymphoproliferative disorder?

Most cases are driven by Epstein-Barr virus: immunosuppression weakens the T-cell control of EBV-infected B cells, allowing them to proliferate, sometimes progressing to lymphoma.

Why are EBV-seronegative recipients at higher risk of PTLD?

An EBV-negative recipient who receives an organ from an EBV-positive donor can acquire a primary EBV infection while immunosuppressed, with little pre-existing immunity to contain it, which raises the risk of EBV-driven PTLD.